South Korean drug manufacturer Samsung Biologics is planning to expand its portfolio of services by adding a mRNA vaccine drug substance (DS) manufacturing line at its facility in Songdo, Seoul.
Biopharmaceutical company CANbridge Pharmaceuticals has signed a licensing agreement with Mirum Pharmaceuticals for the development and commercialisation of maralixibat in Greater China.
GlaxoSmithKline and Vir Biotechnology have announced the European Medicines Agency (EMA) review of VIR-7831 (GSK4182136) for the early treatment of Covid-19.
Takeda Pharmaceutical Company has completed the previously announced sale of a portfolio of select over-the-counter (OTC) pharma products and non-core assets to Orifarm Group for $670m.
Italian pharmaceutical company Fidia Farmaceutici has signed a binding agreement to acquire an integrated portfolio of anti-inflammatory drugs from Sanofi.
Johnson & Johnson’s Janssen Pharmaceutical Companies have announced the US Food and Drug Administration (FDA) approval of PONVORY for the treatment of relapsing forms of multiple sclerosis (MS) in adults.
The US-based clinical stage biopharmaceutical company Boston Pharmaceuticals has announced the signing of a unique three-year out-license and option agreement with the UK-based GlaxoSmithKline (GSK).
The US Food and Drug Administration (FDA) grants orphan drug designation to Ambrx for ARX788, a homogeneous and highly stable antibody drug conjugate, for the treatment of HER2-positive gastric cancer.
Enveric Biosciences has announced that it has signed an exclusive, perpetual licensing agreement with Diverse Biotech to develop new molecules for the treatment of cancer and other debilitating diseases.
WuXi AppTec has acquired OXGENE, a contract research and development organisation in the UK, to strengthen cell and gene therapy service offerings for global customers.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.